PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
18.13%
Growth of 18.13% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
-2.23%
Cost reduction while Drug Manufacturers - Specialty & Generic median is -2.23%. Seth Klarman would investigate competitive advantage potential.
126.49%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.69%. Joel Greenblatt would investigate competitive advantages.
91.73%
Margin expansion exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.62%. Joel Greenblatt would investigate competitive advantages.
119.27%
R&D growth while Drug Manufacturers - Specialty & Generic reduces spending. Peter Lynch would examine strategic differences.
50.66%
G&A change of 50.66% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-5.36%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-101.65%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
49.22%
Operating expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
15.49%
Total costs growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-12.53%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
144.30%
D&A change of 144.30% versus flat Drug Manufacturers - Specialty & Generic D&A. Walter Schloss would verify adequacy.
-43.69%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 15.60%. Seth Klarman would investigate causes.
-361.27%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 5.24%. Seth Klarman would investigate causes.
7.01%
Operating income growth below 50% of Drug Manufacturers - Specialty & Generic median of 23.76%. Jim Chanos would check for deterioration.
21.28%
Operating margin growth near Drug Manufacturers - Specialty & Generic median of 22.15%. Charlie Munger would verify industry dynamics.
-119.25%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 7.36%. Seth Klarman would investigate advantages.
-177.82%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 21.12%. Seth Klarman would investigate causes.
-165.87%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 14.62%. Seth Klarman would investigate causes.
0.38%
Tax expense growth below 50% of Drug Manufacturers - Specialty & Generic median of 18.53%. Joel Greenblatt would investigate efficiency.
-223.94%
Net income decline while Drug Manufacturers - Specialty & Generic median is 13.78%. Seth Klarman would investigate causes.
-204.92%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 10.75%. Seth Klarman would investigate causes.
-151.50%
EPS decline while Drug Manufacturers - Specialty & Generic median is 20.20%. Seth Klarman would investigate causes.
-151.50%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 20.20%. Seth Klarman would investigate causes.
0.66%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.22%. Jim Chanos would check for issues.
0.66%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.07%. Jim Chanos would check for issues.